EXOZHealthcare · BiotechnologyEXOZ Stock Forecast: eXoZymes, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 1 Aug 2026 — in the weakest quartile.
EXOZ stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores eXoZymes, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (5): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own eXoZymes, Inc. — and when they’d sell — is the membership.
EXOZ stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on EXOZ, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
EXOZ analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
eXoZymes, Inc. (EXOZ) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −4.4×
- Price / sales
- —
- Price / book
- 25.8×
- EV / EBITDA
- −4.0×
Cheaper than 89% of US stocks
Cheaper than 4% of US stocks
Cheaper than 77% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −185.8%
- Return on assets
- −81.6%
- Dividend yield
- —
Higher than 7% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
EXOZ vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EXOZ appears on the weeks it earns a place.
Frequently asked questions about EXOZ stock
How does Ticker Nerd's model rank EXOZ?
As at 1 Aug 2026, eXoZymes, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).
What is the EXOZ stock forecast for 2030?
No analyst covering eXoZymes, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EXOZ are extrapolating price history, which says nothing about the business.
How has EXOZ stock performed over the past year?
eXoZymes, Inc. returned -54.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does eXoZymes, Inc. do?
Exozymes Inc. operates in the biotechnology sector with a focus on developing enzyme-based products for industrial applications.
About eXoZymes, Inc.
Exozymes Inc. operates in the biotechnology sector with a focus on developing enzyme-based products for industrial applications. The primary function of Exozymes Inc. is to leverage advanced enzymatic solutions to enhance processes across various industries, including pharmaceuticals, agriculture, and biofuels. Through its innovative approach, the company aims to improve efficiency, reduce environmental impact, and provide sustainable alternatives to traditional chemical processes. Exozymes Inc. plays a key role in the market by offering customizable enzyme solutions that cater to specific industrial needs, thereby driving technological advancements and promoting cleaner manufacturing practices. Its presence underscores the importance of biotechnology in revolutionizing conventional methods and addressing global environmental challenges.
CEO Mr. Michael Heltzen · 32 employees · United States · https://www.exozymes.com